Biotechnology company Bristol Myers Squibb (NYSE: BMY) on Thursday said its second-quarter adjusted earnings decreased year-over-year, hurt by a fall in revenues.
![](data:image/svg+xml;charset=utf-8,<svg height="2021px" width="1280px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
Net income attributable to shareholders was $2.07 billion or $0.99 per share in the June quarter, compared to $1.42 billion or $0.66 per share in the comparable period of 2022. Adjusted profit, meanwhile, declined to $1.75 per share in Q2 from $1.93 per share in the prior-year period.
Second-quarter revenues decreased 6% from last year to $11.23 billion. Domestic revenues declined by 5%, and international revenues dropped by 8%.
![](data:image/svg+xml;charset=utf-8,<svg height="1280px" width="811px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
